CURRENT
ISSUE
1715

The FDA has approved Cobenfy (BMS), an oral fixed-dose combination of the muscarinic agonist xanomeline and the peripheral muscarinic antagonist trospium chloride, for treatment of schizophrenia in adults. It is the first antipsychotic drug to be approved in the US for treatment of schizophrenia that does not block dopamine receptors. This is the first approval for xanomeline; trospium has been available for many years for treatment of overactive bladder.

STANDARD TREATMENT — Drugs that target dopamine receptors are the standard of care for treatment of schizophrenia; second-generation...  Continue reading

Coming Soon
Guselkumab (Tremfya) for Ulcerative Colitis
Drugs for Asthma
Antiviral Drugs for Influenza for 2024-2025
Drugs Past Their Expiration Date